Futura Medical (FUM) - Total Liabilities

Latest as of December 2025: GBX2.41 Million GBX ≈ $293.69 USD

Based on the latest financial reports, Futura Medical (FUM) has total liabilities worth GBX2.41 Million GBX (≈ $293.69 USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Futura Medical - Total Liabilities Trend (2001–2025)

This chart illustrates how Futura Medical's total liabilities have evolved over time, based on quarterly financial data. See Futura Medical current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Futura Medical Competitors by Total Liabilities

The table below lists competitors of Futura Medical ranked by their total liabilities.

Company Country Total Liabilities
Norman Broadbent Plc
LSE:NBB
UK GBX3.98 Million
Cykel AI PLC
LSE:CYK
UK GBX332.83K
Phoenix Global Mining Ltd
LSE:PXC
UK GBX6.58 Million
Unicorn Mineral Resources PLC
LSE:UMR
UK GBX374.10K
t42 IoT Tracking Solutions PLC
LSE:TRAC
UK GBX6.75 Million
Thruvision Group PLC
LSE:THRU
UK GBX2.14 Million
Getech Group
LSE:GTC
UK GBX2.48 Million
Adomos SA
PA:ALADO
France €11.25 Million

Liability Composition Analysis (2001–2025)

This chart breaks down Futura Medical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Futura Medical worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.06 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.86 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Futura Medical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Futura Medical (2001–2025)

The table below shows the annual total liabilities of Futura Medical from 2001 to 2025.

Year Total Liabilities Change
2025-12-31 GBX2.41 Million
≈ $293.69
-47.84%
2024-12-31 GBX4.63 Million
≈ $563.01
-27.01%
2023-12-31 GBX6.34 Million
≈ $771.34
+261.62%
2022-12-31 GBX1.75 Million
≈ $213.30
-15.64%
2021-12-31 GBX2.08 Million
≈ $252.85
+171.12%
2020-12-31 GBX766.52K
≈ $93.26
-84.19%
2019-12-31 GBX4.85 Million
≈ $589.80
+139.32%
2018-12-31 GBX2.03 Million
≈ $246.45
+305.80%
2017-12-31 GBX499.14K
≈ $60.73
-41.63%
2016-12-31 GBX855.18K
≈ $104.05
+17.29%
2015-12-31 GBX729.12K
≈ $88.71
+19.94%
2014-12-31 GBX607.89K
≈ $73.96
+27.17%
2013-12-31 GBX478.00K
≈ $58.16
+42.71%
2012-12-31 GBX334.95K
≈ $40.75
+72.66%
2011-12-31 GBX194.00K
≈ $23.60
+27.63%
2010-12-31 GBX152.00K
≈ $18.49
-32.14%
2009-12-31 GBX224.00K
≈ $27.25
+47.37%
2008-12-31 GBX152.00K
≈ $18.49
-51.75%
2007-12-31 GBX315.00K
≈ $38.33
+33.47%
2006-12-31 GBX236.00K
≈ $28.71
-0.42%
2005-12-31 GBX237.00K
≈ $28.84
+5.33%
2004-12-31 GBX225.00K
≈ $27.38
+25.00%
2003-12-31 GBX180.00K
≈ $21.90
-27.13%
2003-01-31 GBX247.00K
≈ $30.05
-5.73%
2002-01-31 GBX262.00K
≈ $31.88
-58.41%
2001-01-31 GBX630.00K
≈ $76.65
--

About Futura Medical

LSE:FUM UK Biotechnology
Market Cap
$38.34K
GBX315.08 Million GBX
Market Cap Rank
#31462 Global
#1236 in UK
Share Price
GBX0.54
Change (1 day)
+0.37%
52-Week Range
GBX0.53 - GBX13.43
All Time High
GBX84.52
About

Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company's lead product includes Eroxon, a topical gel for the treatment of erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Fut… Read more